Veracyte (VCYT)
(Delayed Data from NSDQ)
$32.84 USD
-0.13 (-0.39%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $32.96 +0.12 (0.37%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$32.84 USD
-0.13 (-0.39%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $32.96 +0.12 (0.37%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth A Momentum B VGM
Zacks News
Globus Medical (GMED) Global Sales, Innovation Aid Growth
by Zacks Equity Research
In line with the company's business strategy to focus on its integrated product development, Globus Medical (GMED) is consistently making efforts in research and development.
Globus Medical (GMED) Gets FDA Nod for ExcelsiusFlex, ACTIFY 3D
by Zacks Equity Research
Globus Medical (GMED) gets the FDA 510(k) clearance for its ExcelsiusFlex with Total Knee Arthroplasty application and ACTIFY 3D Total Knee System.
Veracyte (VCYT) Stock Jumps 13.2%: Will It Continue to Soar?
by Zacks Equity Research
Veracyte (VCYT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Take the Zacks Approach to Beat the Markets: NVIDIA, Twist Bioscience, Ollie's Bargain Outlet in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
AxoGen (AXGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
3 Medical Instruments Picks to Navigate Industry Challenges
by Urmimala Biswas
Deteriorating geopolitical situation and supply bottlenecks mar the prospects of the Zacks Medical Instruments industry. Yet, HOLX, MASI and VCYT are worth buying based on strategic developments and fundamentals.
Zacks.com featured highlights Veracyte, Steelcase and Applied Industrial
by Zacks Equity Research
Veracyte, Steelcase and Applied Industrial have been highlighted in this Screen of The Week article.
3 Top-Ranked Efficient Stocks to Increase Your Portfolio Returns
by Santanu Roy
Invest in companies like Veracyte (VCYT), Steelcase (SCS) and Applied Industrial Technologies (AIT), as they boast higher efficiency levels.
Wall Street Analysts See a 37.09% Upside in Veracyte (VCYT): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Veracyte (VCYT) points to a 37.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Veracyte (VCYT) Up 8.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.07%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 39.1% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Veracyte (VCYT) Crossed Above the 50-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
Zacks.com featured highlights include Veracyte, Signet Jewelers, UMB Financial and NVIDIA
by Zacks Equity Research
Veracyte, Signet Jewelers, UMB Financial and NVIDIA are part of the Zacks Screen of the Week article.
Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
4 Must-Buy Efficient Stocks to Enrich Your Portfolio
by Santanu Roy
Invest in companies like Veracyte (VCYT), Signet Jewelers (SIG), UMB Financial (UMBF) and NVIDIA (NVDA) to make the most of higher efficiency levels.
Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care
by Zacks Equity Research
Veracyte's (VCYT) new studies leverage Afirma GRID's whole-transcriptome approach to uncover novel molecular signatures and alterations.
Buy 5 Medical Instruments Stocks to Enhance Your Portfolio
by Nalak Das
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These stocks are: ALC, RXST, HOLX, VCYT, MASI.
Veracyte (VCYT) Up 6% Since Last Earnings: Will it Continue?
by Zacks Equity Research
Investors are optimistic about Veracyte (VCYT) led by strength in the testing business and upbeat guidance.
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 39.59%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Veracyte (VCYT) points to a 39.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's How Medtronic (MDT) Is Placed Ahead of Q4 Earnings
by Moumi Mondal
Medtronic's (MDT) rapid cadence of new product approvals is a strong foundation for future growth. However, the company also navigates some macroeconomic challenges.
Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View
by Zacks Equity Research
Veracyte's (VCYT) first-quarter 2024 performance reflects the strength of its testing business.
Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 54.55% and 3.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands
by Zacks Equity Research
Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.